3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Conditions
Multiple Myeloma
68
Recurrence
7
Smoldering Multiple Myeloma
4
Neoplasms
4
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
3
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Plasmablastic Lymphoma
2
Lymphoma
2
Leukemia, Myeloid, Acute
2
Immunoglobulin Light-chain Amyloidosis
2
Plasmacytoma
1
Paraproteinemias
1
Neoplasms, Plasma Cell
1
Myelodysplastic Syndromes
1
Lymphoma, Large B-Cell, Diffuse
1
Leukemia, Plasma Cell
1
Glioblastoma
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
pomalidomide
1
daratumumab
1
Immunotherapy, Adoptive
1
Dexamethasone
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Plasmacytoma
×
daratumumab
×
90 days
×
Clear all
NCT01946477
2026-05-22
POM MM 014
Celgene
Phase 2
Completed
186 enrolled
17 charts